Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.53
+0.11000.71%
Post-market: 15.530.00000.00%19:30 EDT
Volume:3.29M
Turnover:51.08M
Market Cap:3.13B
PE:-18.79
High:15.62
Open:15.62
Low:15.39
Close:15.42
52wk High:16.20
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.94
T/O Rate:1.68%
Dividend:1
Dividend Rate:6.44%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:1.01
PE(LYR):-10.86

Loading ...

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

GlobeNewswire
·
Jun 11

Nyse Order Imbalance 759031.0 Shares on Sell Side

THOMSON REUTERS
·
Jun 11

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

GlobeNewswire
·
Jun 09

UBS Adjusts Price Target on Park Hotels & Resorts to $14 From $11, Maintains Neutral Rating

MT Newswires Live
·
Jun 08

College Entrance Exam Essays in Beijing and Shanghai Test AI! Three Leading Models Compete: Who Writes the Best Essay?

Deep News
·
Jun 07

Court Orders Gym to Repay Mandatory "Performance Competition" Fees Collected from Employee

Deep News
·
Jun 06

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

GlobeNewswire
·
Jun 06

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

Park Hotels & Resorts updates financial calendar with Q2 earnings release, conference call

Reuters
·
Jun 03

Press Release: Park Hotels & Resorts Inc. Announces Second Quarter 2026 Earnings Conference Call on August 7, 2026

Dow Jones
·
Jun 03

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

GlobeNewswire
·
Jun 03

World Cup Poised to Lift REITs with Full-Service Hotel Exposure -- Market Talk

Dow Jones
·
Jun 03

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Jun 01

Park Hotels forecasts FY 2026 adjusted EBITDA of $587 million-$617 million

Reuters
·
Jun 01

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026

GlobeNewswire
·
Jun 01

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

GlobeNewswire
·
May 29

Park Hotels & Resorts (PK) Is Up 9.1% After Strong Q1 RevPAR Beat And Non-Core Asset Sale

Simply Wall St.
·
May 28

Park Hotels & Resorts Is Maintained at Hold by Truist Securities

Dow Jones
·
May 27

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

GlobeNewswire
·
May 26

Truist Raises Price Target on Park Hotels & Resorts to $13 From $12, Keeps Hold Rating

MT Newswires Live
·
May 26